Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

4.79
+0.24005.27%
Pre-market: 4.920.1300+2.71%04:46 EDT
Volume:2.22M
Turnover:10.54M
Market Cap:368.90M
PE:-3.58
High:4.89
Open:4.43
Low:4.37
Close:4.55
Loading ...

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

GlobeNewswire
·
25 Feb

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Business Wire
·
25 Feb

ALT Resources to Acquire Mining Royalty and Move to AIM

TIPRANKS
·
24 Feb

3 Token Unlocks to Watch for The Last Week of February

BE[IN]CRYPTO
·
24 Feb

Altimmune put volume heavy and directionally bearish

TIPRANKS
·
19 Feb

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

GlobeNewswire
·
18 Feb

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

GlobeNewswire
·
12 Feb

Altimmune call volume above normal and directionally bullish

TIPRANKS
·
12 Feb

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Business Wire
·
11 Feb

Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Feb

With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns

Simply Wall St.
·
04 Feb

B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)

TIPRANKS
·
28 Jan

Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
23 Jan

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

GlobeNewswire
·
22 Jan

Altimmune call volume above normal and directionally bullish

TIPRANKS
·
18 Jan

FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

PR Newswire
·
17 Jan

Stifel Initiates Altimmune at Buy With $18 Price Target

MT Newswires Live
·
08 Jan

Evercore ISI Keeps Their Buy Rating on Altimmune (ALT)

TIPRANKS
·
08 Jan

Altimmune Inc : Stifel Initiates Coverage With Buy Rating; Price Target $18

THOMSON REUTERS
·
08 Jan

Innovative Breakthrough in Metabolic Disease Treatment: Annabel Samimy’s Buy Rating on Altimmune’s Pemvidutide

TIPRANKS
·
08 Jan